Gilead Sciences, Inc (GILD) is a leading drug manufacturers-general business based in the US. It opened the day at $68.91 after a previous close of $68.91. During the day the price has varied from a low of $68.3884 to a high of $69.18. The latest price was $68.53 (25 minute delay). Gilead Sciences is listed on the NASDAQ and employs 13,600 staff. All prices are listed in US Dollars.
Since the stock market crash that started in February 2020, Gilead Sciences's share price has had significant negative movement.
Its last market close was $62.79, which is 9.91% down on its pre-crash value of $69.7 and 2.04% down on the lowest point reached during the March 2020 crash when the shares fell as low as $64.07.
If you had bought $1,000 worth of Gilead Sciences shares at the start of February 2020, those shares would have been worth $1,094.23 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $946.25.
|52-week range||$55.9038 - $76.3778|
|50-day moving average||$65.7797|
|200-day moving average||$63.112|
|Wall St. target price||$74.54|
|Dividend yield||$2.75 (3.99%)|
|Earnings per share (TTM)||$0.24|
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
|Platform||Platform fee||Min. initial deposit||Trading fee estimate|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|£9.99 per month||No minimum||£15.31
|Capital at risk|
|Capital at risk|
|£36 per year||£20||£15.60
|Capital at risk|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 month (2021-04-16)||2.48%|
|3 months (2021-02-16)||5.76%|
|6 months (2020-11-16)||12.18%|
|1 year (2020-05-15)||-10.14%|
|2 years (2019-05-16)||4.18%|
|3 years (2018-05-16)||1.45%|
|5 years (2016-05-16)||-18.04%|
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 286x. In other words, Gilead Sciences shares trade at around 286x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Gilead Sciences's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4957. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Gilead Sciences's PEG ratio in relation to those of similar companies.
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $13.3 billion (£9.4 billion).
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
|Revenue TTM||$25.6 billion|
|Operating margin TTM||45.69%|
|Gross profit TTM||$21 billion|
|Return on assets TTM||11.48%|
|Return on equity TTM||1.33%|
|Market capitalisation||$85.9 billion|
TTM: trailing 12 months
There are currently 28.6 million Gilead Sciences shares held short by investors – that's known as the "short interest". This figure is 10.1% up from 26.0 million last month.
There are a few different ways that this level of interest in shorting Gilead Sciences shares can be evaluated.
Gilead Sciences's "short interest ratio" (SIR) is the quantity of Gilead Sciences shares currently shorted divided by the average quantity of Gilead Sciences shares traded daily (recently around 6.9 million). Gilead Sciences's SIR currently stands at 4.15. In other words for every 100,000 Gilead Sciences shares traded daily on the market, roughly 4150 shares are currently held short.
To gain some more context, you can compare Gilead Sciences's short interest ratio against those of similar companies.
However Gilead Sciences's short interest can also be evaluated against the total number of Gilead Sciences shares, or, against the total number of tradable Gilead Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gilead Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Gilead Sciences shares in existence, roughly 20 shares are currently held short) or 0.0228% of the tradable shares (for every 100,000 tradable Gilead Sciences shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gilead Sciences.
Find out more about how you can short Gilead Sciences stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
Gilead Sciences's total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Gilead Sciences's total ESG risk score against those of similar companies.
Gilead Sciences's environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Gilead Sciences's social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Gilead Sciences's governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Gilead Sciences's controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
|Total ESG score||22.15|
|Total ESG percentile||30.98|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
Dividend payout ratio: 36.72% of net profits
Recently Gilead Sciences has paid out, on average, around 36.72% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.12% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 4.12% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.75 per share.
While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
Gilead Sciences's most recent dividend payout was on 28 June 2021. The latest dividend was paid out to all shareholders who bought their shares by 13 June 2021 (the "ex-dividend date").
Gilead Sciences's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Gilead Sciences's shares were split on a 2:1 basis on 27 January 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $55.9038 up to $76.3778. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.3989. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
To put Gilead Sciences's beta into context you can compare it against those of similar companies.
Ever wondered how to buy shares in CarGurus? We explain how and compare a range of providers that can give you access to many brands, including CarGurus.
Ever wondered how to buy shares in SemiLEDs? We explain how and compare a range of providers that can give you access to many brands, including SemiLEDs.
Everything we know about the TikTok IPO, plus information on how to buy it.
Everything we know about the Robinhood IPO, plus information on how to buy it.
Ever wondered how to buy shares in Lexaria Bioscience? We explain how and compare a range of providers that can give you access to many brands, including Lexaria Bioscience.
Ever wondered how to buy shares in Stealth BioTherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Stealth BioTherapeutics.
Ever wondered how to buy shares in iBio? We explain how and compare a range of providers that can give you access to many brands, including iBio.
Everything we know about the Endeavor Group IPO, plus information on how to buy it.
Ever wondered how to buy shares in Farmmi? We explain how and compare a range of providers that can give you access to many brands, including Farmmi.
Ever wondered how to buy shares in Pure Cycle? We explain how and compare a range of providers that can give you access to many brands, including Pure Cycle.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.